Stepping back and viewing the epidemiology of hypertrophic cardiomyopathy (HCM) from a chronological perspective reveals many reasons for optimism. In contemporary series of HCM patients from adolescence through adulthood, annual disease-related mortality is estimated at 0.5%, similar to that of the general population, with >60% of survivors reporting normal exertional capacity (NYHA class I) 1,2 . In children, the evaluation of both morbidity and mortality is complicated by the influence of aetiology on disease course. After excluding inborn errors of metabolism, malformation syndromes, and neuromuscular disorders, however, children with HCM who survive infancy have an annual mortality of 1% 3 . Such favourable outcomes contrast with accounts of HCM from half a century ago. Of the eight patients described in Donald Teare's now-classic description of asymmetric hypertrophy of the interventricular septum, seven had died suddenly before the age of 45 years 4 . The French-Canadian family in whom the hereditary basis of HCM was established, and the first causal mutation identified, had suffered numerous losses from both cerebrovascular accidents and sudden cardiac death (SCD) 5 . In HCM cohorts from tertiary centres in the 1970s and early 1980s, the annual death rates were as high as 2-4% in adults and 4.2-5.9% in children 2, 3, [6] [7] [8] . The apparent decline in morbidity and mortality in patients with HCM over the past few decades can be partly attributed to awareness of, and adjustment for, the selection bias inherent in tertiary centre studies. Debilitating symptoms were significantly less prevalent among patients with HCM at regional centres than at referral units (4% versus 44%) 9 . From 1981 to 2002, disease-related mortality among patients with HCM was 1.3-1.4% per year according to studies that limited selection bias, either by sampling from a regional centre, or by including affected relatives 10, 11 . These estimates remain, however, almost threefold higher than those from contemporary studies, suggesting that other factors are also important 1,2 . Chief among them is the advent of both modern external and implantable cardioverter-defibrillators (ICDs). In a 2016 study Abstract | Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disorder, affecting 1 in 500 individuals worldwide. Existing epidemiological studies might have underestimated the prevalence of HCM, however, owing to limited inclusion of individuals with early, incomplete phenotypic expression. Clinical manifestations of HCM include diastolic dysfunction, left ventricular outflow tract obstruction, ischaemia, atrial fibrillation, abnormal vascular responses and, in 5% of patients, progression to a 'burnt-out' phase characterized by systolic impairment. Disease-related mortality is most often attributable to sudden cardiac death, heart failure, and embolic stroke. The majority of individuals with HCM, however, have normal or near-normal life expectancy, owing in part to contemporary management strategies including family screening, risk stratification, thromboembolic prophylaxis, and implantation of cardioverter-defibrillators. The clinical guidelines for HCM issued by the ACC Foundation/AHA and the ESC facilitate evaluation and management of the disease. In this Review, we aim to assist clinicians in navigating the guidelines by highlighting important updates, current gaps in knowledge, differences in the recommendations, and challenges in implementing them, including aids and pitfalls in clinical and pathological evaluation. We also discuss the advances in genetics, imaging, and molecular research that will underpin future developments in diagnosis and therapy for HCM.
Stepping back and viewing the epidemiology of hypertrophic cardiomyopathy (HCM) from a chronological perspective reveals many reasons for optimism. In contemporary series of HCM patients from adolescence through adulthood, annual disease-related mortality is estimated at 0.5%, similar to that of the general population, with >60% of survivors reporting normal exertional capacity (NYHA class I) 1, 2 . In children, the evaluation of both morbidity and mortality is complicated by the influence of aetiology on disease course. After excluding inborn errors of metabolism, malformation syndromes, and neuromuscular disorders, however, children with HCM who survive infancy have an annual mortality of 1% 3 . Such favourable outcomes contrast with accounts of HCM from half a century ago. Of the eight patients described in Donald Teare's now-classic description of asymmetric hypertrophy of the interventricular septum, seven had died suddenly before the age of 45 years 4 . The French-Canadian family in whom the hereditary basis of HCM was established, and the first causal mutation identified, had suffered numerous losses from both cerebrovascular accidents and sudden cardiac death (SCD) 5 . In HCM cohorts from tertiary centres in the 1970s and early 1980s, the annual death rates were as high as 2-4% in adults and 4.2-5.9% in children 2, 3, [6] [7] [8] . The apparent decline in morbidity and mortality in patients with HCM over the past few decades can be partly attributed to awareness of, and adjustment for, the selection bias inherent in tertiary centre studies. Debilitating symptoms were significantly less prevalent among patients with HCM at regional centres than at referral units (4% versus 44%) 9 . From 1981 to 2002, disease-related mortality among patients with HCM was 1.3-1.4% per year according to studies that limited selection bias, either by sampling from a regional centre, or by including affected relatives 10, 11 . These estimates remain, however, almost threefold higher than those from contemporary studies, suggesting that other factors are also important 1, 2 . Chief among them is the advent of both modern external and implantable cardioverter-defibrillators (ICDs). In a 2016 study 1 of young patients with HCM (mean age 20 ± 5 years), the annual incidence of resuscitated out-of-hospital cardiac arrest and ICD discharge for ventricular tachyarrhythmia was 0.6% and 0.9%, respectively 2 . Evidence-based risk stratifi cation algorithms facilitate identification of the patients with HCM most likely to benefit from ICD therapy.
Although ICDs have revolutionized the prevention of SCD, not all discharges in individuals with nonischaemic heart disease are a reliable surrogate for resuscitated cardiac arrest, particularly when interventions for ventricular tachycardia are included in the end point 12 . The improvements in survival and quality of life of patients with HCM might owe as much to the following factors: development of reliable imaging and rhythm monitor ing; timely diagnosis of index cases; identification of phenotypic mimics (with implications for management); prospective evaluation of relatives (aided in some famil ies by genetic analysis); the ability to link dyspnoea, angina, and other common symptoms to underlying causes such as diastolic dysfunction, left ventricular (LV) outflow tract obstruction (LVOTO), and ischaemia; avail ability of safe and effective pharmacotherapy for most complications (TABLE 1) ; honing of techniques for invasive septal reduction in drug-refractory LVOTO; and framing of consensus guidelines that have standardized evaluation and rationalized the numerous available treatment options [13] [14] [15] [16] [17] [18] . The benefit of simple measures, such as early detection of atrial fibrillation to enable prophylactic anti coagulation, and discouraging individuals with a confirmed diagnosis of HCM from engaging in competitive sports, should also not be discounted. The latter might be the single most common piece of lifestyle advice offered to individuals with HCM; supportive evidence comes indirectly from the Italian preparticipation screening programme, which has been associated with an 89% decline in the incidence of SCD among athletes 19 . No concomitant change has been observed in the incidence of SCD in the unscreened non athletic population, nor any deaths among the athletes diagnosed with HCM, pointing to a potential benefit from sports disqualification per se. From an objective vantage point, consider able progress has been made in the understanding, evaluation, and management of HCM.
Conversely, individuals with HCM might feel there is little room for complacency. Many have been labelled, often at a young age, with a diagnosis that has implications for obtaining mortgages and life insurance, and requires lifelong follow-up. The disease will at worst result in SCD, stroke, or progressive heart failure, and at best remain stable, but with no prospect of remission. No cure currently exists for HCM, and the available treatment options -ranging from drug therapy to septal reduction and device implantation -are not without possible adverse effects or complications 14, 15 . Furthermore, HCM is most commonly inherited in an autosomal dominant fashion, which translates into a 50% probability of transmitting the causal mutation to offspring.
The challenge of determining risk-benefit ratios for any form of treatment should be familiar to health-care providers, who have the additional burden of uncertainties about evaluation, diagnosis, and surveillance of patients with HCM. The comprehensive clinical guidelines issued by the ACC Foundation (ACCF)/AHA and ESC equip clinicians to make informed decisions, but they are not a panacea in the management of HCM 14, 15 . Policy makers, health service chiefs, and subspecialty experts harbour concerns about heterogeneous implementation of the guidelines, the accessibility and quality of imaging and ancillary investigations (particularly at nonreferral units), and whether sufficient clinical experi ence and support systems such as genetic counselling are available in primary and secondary care settings.
Gaps in both knowledge and understanding of HCM also remain. Owing to the paucity of randomized clinical trials and large-scale studies, most recommendations are based on consensus opinion of experts, small-scale and retrospective studies, and registries; further data are awaited to resolve a number of outstanding issues 14, 15 . Detailed guidance is available, for example, on differentiating HCM from left ventricular hypertrophy (LVH) secondary to hypertension or athletic adaptation, but interpretation of the requisite investigations in African-Caribbean individuals continue to pose difficulties, as does the distinction of late-onset HCM from isolated basal septal hypertrophy (IBSH) in the elderly 15 .
Nowhere is the scarcity of knowledge more apparent, however, than in the management of relatives with subclinical or incomplete phenotypic expression, increasingly identified by sophisticated imaging techniques and mutation screening.
Previously available only to highly selected families attending referral units with research laboratories, genetic testing has now been pushed to the forefront
Key points
• Although the ACC Foundation (ACCF)/AHA and ESC guidelines show widespread concordance, the ESC definition of hypertrophic cardiomyopathy (HCM) includes nonsarcomeric disease states associated with load-independent left ventricular hypertrophy (LVH) • Relatives of patients with HCM should be offered screening; autosomal dominant inheritance is typical, and a range of electrocardiographic and imaging features are recognized to precede the development of LVH • Prognostic assessment at baseline and follow-up is recommended for all patients with HCM; despite recognizing many of the same predictors of sudden death, the ACCF/AHA and ESC adopt distinct approaches to risk profiling • Specialist HCM centres promote implementation of best-practice guidelines by offering facilities and skills for investigations such as exercise stress echocardiography, cardiovascular magnetic resonance (CMR), and genetic analysis, in addition to high-volume programmes for invasive septal reduction • Patients referred to specialist HCM centres also benefit from multidisciplinary support systems and clinical experience in interpreting equivocal clinical findings, adjudicating borderline risk profiles, and managing complex cases • Advances in the evaluation of HCM include CMR-based T1 mapping for demonstrating diffuse and interstitial fibrosis; in the therapeutic arena, several putative substrate-modulating agents are progressing from preclinical to clinical trials of the clinical arena by rapid advances in genotyping technology and large genomic repositories, which have also provided a powerful platform for genetics research. Despite simultaneous progress in bioinformatics, a bottle neck has arisen in the analysis and interpret ation of the vast quantities of raw complex data produced. Already, however, gene variants previously presumed pathogenic are being reclassified as benign or modifying, and vice versa 20 . The translational research needed to integrate the new genetic discoveries into clinical practice is lagging further behind.
In this Review, we aim to assist clinicians in navigating the 2011 ACCF/AHA 14 and 2014 ESC 15 guidelines for HCM by surveying the main points of divergence, key updates, unresolved issues, and challenges in implementation, including aids and pitfalls in diagnosis. We also discuss the effect of the latest advances in genetics and imaging on early diagnosis of the disease, and briefly highlight ongoing efforts to elucidate the molecular mechanisms underpinning the disease, which hold promise of substrate-modulating therapy in the not-too-distant future. • Resting LVOT gradient ≥30 mmHg is a predictor of both all-cause mortality and arrhythmic events, but whether pharmacotherapy reduces this risk is currently unresolved. The incidence of SCD in asymptomatic individuals with resting LVOTO as their sole risk factor is estimated at <0.4%, arguing against intervention for prognostic reasons. Treatment is, therefore, directed towards symptom relief • General advice is to ensure adequate filling and avoid vasodilators such as amlodipine and positive inotropic agents such as digoxin • Nonvasodilating β-blockers are used as first-line therapy and are particularly effective for exertional LVOTO • Disopyramide is used as an add-on to β-blockers, particularly for symptomatic resting LVOTO; dose is titrated according to tolerance of anticholinergic adverse effects. Monitoring of QT interval is advised, with avoidance of other QT-prolonging agents (for example, amiodarone and sotalol) • Disopyramide plus verapamil/diltiazem can be used if β-blockers are contraindicated • Disopyramide should not be used as monotherapy in the presence of atrial fibrillation because it might accelerate the ventricular response rate • Verapamil/diltiazem can also be used as monotherapy if β-blockers are contraindicated, but caution is warranted, particularly in the presence of severe LVOTO • In the rare setting of hypotension or pulmonary oedema secondary to acute LVOTO, patients who do not respond adequately to filling might benefit from intravenous β-blockers and/or vasoconstrictors such as phenylephrine • Invasive septal reduction is an option for patients with NYHA class III-IV symptoms despite maximum tolerated pharmacotherapy
• If obstructive coronary artery disease is unlikely or has been excluded, microvascular ischaemia can be presumed • Nondihydropyridine calcium-channel blockers such as verapamil or diltiazem are often used first line in this setting; β-blockers are an alternative
Atrial fibrillation
• Consider anticoagulation (CHA 2 DS 2 -VASc score not recommended for use in patients with HCM)
• Rhythm control with sotalol or amiodarone (with variable success)
• Rate control with β-blockers or nondihydropyridine calcium-channel blockers Ventricular arrhythmia
• Nonsustained VT on ambulatory ECG monitoring is a risk factor for SCD; amiodarone plus β-blockers might suppress ventricular extrasystoles and nonsustained VT, and appeared, in studies from the pre-ICD era, to confer a survival benefit. In contemporary practice, ICD therapy is first line for individuals with a high-risk profile • Sustained VT is uncommon and warrants evaluation for coexisting coronary artery disease and/or LV apical aneurysm with adjacent scarring. ICD is indicated for prevention of SCD; β-blockers and/or amiodarone are often of benefit in suppressing arrhythmia
Abnormal vascular responses
• Symptoms of impaired consciousness • Failure of systolic BP to rise by ≥20 mmHg during maximal upright exercise testing or fall >20 mmHg from peak pressure
• The selective serotonin reuptake inhibitor paroxetine has been shown to reverse paradoxical vasodilatation, alleviate associated symptoms, and augment systolic BP in patients with HCM with an abnormal BP response to upright exercise • Pharmacological therapy for vascular instability has the potential to be of both symptomatic and risk-modifying benefit, but remains largely empirical until further data become available Wall thinning and cavity dilatation
• Symptoms of heart failure • Conventional therapy for systolic heart failure (including angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers, β-blockers, and diuretics if necessary) 
Controversies in defining HCM
HCM is a heritable disorder of the heart muscle with a well-described pathological, clinical, and genetic profile. Typical pathological findings include LVH, myocyte disarray, small-vessel disease, and both replacement and interstitial fibrosis 21 . Recognized clinical manifestations of HCM include diastolic dysfunction, LVOTO, mitral regurgitation, inappropriate vasodilatation during exertion, microvascular ischaemia, atrial fibrillation, ventricular arrhythmia, and SCD (TABLE 1 ). An estimated 0.5% of patients per year progress to 'burnt-out' HCM, characterized by wall thinning, cavity dilatation, and systolic dysfunction, sometimes accompanied by moderate-to-severe pulmonary hypertension [13] [14] [15] [16] [17] [18] 21, 22 . Among HCM cases of known aetiology, mutations in genes encoding components of the sarcomere -the contractile apparatus of the cell -predominate in every age group beyond infancy. The most commonly implicated mutations are located within the thick-filament genes that encode myosin 7 (MYH7) and cardiac myosin-binding protein C (MYBPC3), but a sizeable minority of patients harbour defects in thin-filament genes, including TNNT2, TNNI3, TPM1, and ACTC. None of these features, however, is pathognomonic of HCM, and no universally accepted definition for the disease exists.
The ACCF/AHA and ESC definitions for HCM overlap considerably, but differ in breadth. According to the ACCF/AHA, HCM is a disease state characterized by unexplained LVH associated with nondilated ventricular chambers in the absence of another cardiac or systemic disease that itself could produce the magnitude of hypertrophy evident in a given patient, with the caveat that patients who are genotype-positive might be phenotypically negative without overt hypertrophy 14 . The ESC defines HCM as the presence of increased LV wall thickness that is not solely explained by abnormal loading conditions 15 . Notably, both definitions are based on the presence of LVH, although this requirement is not without its drawbacks; both also exclude Disease course is frequently distinct from that of sarcomeric HCM
• LVH in infants of diabetic mothers typically resolves spontaneously within the first 6 months of life • Danon disease: early severe LVH, followed by cavity dilatation and systolic dysfunction with rapid deterioration to end-stage heart failure Vigilance for extracardiac complications might be necessary
• AFD: increased risk of cerebrovascular accident and declining glomerular filtration rate (might be slowed by combined therapy with agalsidase alfa and renin-angiotensin system inhibitors) • PRKAG2 (AMP-kinase) disease: progressive conduction system defects and ventricular pre-excitation
Therapeutic options
Interventions that are highly effective in patients with archetypal HCM might be less so in phenotypic mimics
• hypertrophy that is exclusively load-induced, while allowing for possible coexistence of pressure/volume loading states with HCM.
Phenotypic mimics of sarcomeric HCM. LVH resembling archetypal sarcomeric HCM is also observed in a number of other disease states, accounting for an estimated 5% of adult and a still higher proportion of childhood cases 15 (TABLE 2) . The often-used designation of 'phenocopy' refers specifically to an environ mentally determined disease state that mimics a heritable disorder. In common parlance, however, the term phenocopy is also widely applied to genetic disorders with cardiac phenotypes akin to HCM (strictly, 'genocopies'). One point of contention between the current guidelines is that the ESC classifies phenocopies and genocopies within the spectrum of HCM, whereas the narrower ACCF/AHA definition specifically excludes them. Semantics aside, however, timely recognition of phenotypic mimics is important because of their distinctive clinical profiles, natural histories, therapeutic options, and inheritance patterns 15, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] (TABLE 2) .
Limitations of LVH-based HCM definition.
One shortcoming shared by both the ESC and ACCF/AHA definitions of HCM is the stipulation of LVH for a diagnosis of HCM 14, 15 . One of the best documented examples of disease expression without LVH was originally observed on postmortem examination of four individuals from the same family who suffered SCD 39 . Their hearts appeared macroscopically normal, with weights, cavity size, and wall thickness within reference ranges; histological analysis, however, revealed widespread myocardial disarray 39 . A mutation in the thin-filament gene TNNT2 was subsequently identified in the family, including in a surviving relative in whom echo cardiography was unremark able, but 12-lead electro cardiogram (ECG) and blood-pressure response to exercise were abnormal 40 . A further postmortem series affirmed the occurrence of premature SCD in individuals with TNNT2 mutations and severe myocyte disarray, but minimal LVH and fibrosis 41 . A more complete picture of troponin T disease emerged from a study involving 71 adults and 21 children (aged ≤16 years) with TNNT2 mutations from 20 families 42 . Among the adults, 76% had abnormalities on echocardiography, and all arrhythmic events occurred in individuals with 15-27 mm of LVH. By contrast, echocardiography was normal in 90% of the children, including one patient who experienced SCD despite LV wall thickness of only 9 mm. Aside from a family history of SCD, the most common indicator of adverse outcome was an abnormal blood-pressure response to exercise, which was observed in 48% of adults and 40% of children, and sometimes preceded the appearance of LVH 42 . A subsequent study found that maximal wall thickness (MWT) was lower and LVOTO was less prevalent among unrelated index cases with thin (n = 80) versus thick (n = 150) filament mutations 43 , whereas systolic dysfunction, restrictive LV filling, and progression to NYHA class III and IV were significantly Nature Reviews | Cardiology more common; no difference was observed in the incidence of arrhythmic events 43 . Taken together, the available data show no evidence of increased arrhythmic risk in patients with thin filament disease, but suggest that expression of LVH is milder and age-dependent [40] [41] [42] [43] ; SCD in the absence of LVH is uncommon but recognized, with extensive myocyte disarray the most likely substrate [40] [41] [42] [43] .
The question then arises: should the defining feature of HCM be myocyte disarray instead of LVH? Although myocyte disarray is the histological hallmark of HCM, it is not specific for sarcomeric disease, and has also been documented in genocopies including Anderson-Fabry disease, Noonan syndrome, and Friedreich ataxia, but not PRKAG2 mutations [44] [45] [46] . On ex vivo examination, myocyte disarray is more widespread in the hearts of individuals who showed an abnormal blood-pressure response to exercise, features of ischaemia (chest pain, marked ST-segment depression on exercise testing, and/or perfusion defects), or died suddenly 47 . A direct clinical surrogate for myocyte disarray does not, however, exist and the consequent inability to assess its presence or extent in vivo is the chief limitation of a definition based on histology.
Defining HCM on the basis of genetics, as a disease of the sarcomere, has the dual advantages of being readily testable and encompassing otherwise subclinical disease forms. The prevalence of sarcomeric mutations among both adults and children with HCM varies from 40-60%, depending, among other factors, on the panel of genes screened and the study population 15 . Accessory and related proteins in the sarcomere (for example, myosin light chain kinase 2 and phospholamban) are also implicated in HCM, albeit in a minority of cases 15 . Outside its scope, as in the ACCF/AHA guidelines, are the 5-10% of HCM cases with pheno copies or geno copies, which might be justifiable on the grounds of distinct disease profiles 14, 15 . Less justifiable from a clinical standpoint is the exclusion of the residual 25-30% of patients with HCM who have archetypal disease, but no detectable mutation in the known disease-causing genes 15 .
Another argument against the genetic definition for HCM is its lack of specificity. The same defects in TNNI3, for example, underlie both HCM and restrictive cardiomyopathy in some families (FIG. 1) , whereas other sarcomeric mutations have been implicated in dilated cardiomyopathy [48] [49] [50] [51] . A mechanistic definition has been proposed, which shifts the putative final common pathway of HCM from the sarcomere to primary cellular energy depletion, thereby offering a unifying therapeutic target 52 . The fundamental premise, however, has not yet gained widespread acceptance.
Challenges in evaluation
Clinicians, imaging specialists, and geneticists alike are confronted by a number of challenges in the evaluation of HCM. Experience aids in avoiding the common pitfalls, some of which are discussed below, but uncertainties persist in a few critical areas (such as the differentiation of HCM from IBSH, and interpretation of genetic variants of unknown significance) owing to an incomplete knowledge base 14, 15 . The diagnosis is not always straightforward even on pathology, notwithstanding the ability to examine the whole heart at both macroscopic and microscopic levels 21 
Clinical work-up for HCM. The preliminary work-up for an individual with suspected HCM includes obtaining a clinical history, compiling a pedigree, physical examination, 12-lead ECG, and imaging, typically 2D echocardiography
. Maximal upright exercise testing and rhythm monitoring are indicated in confirmed cases Box 1 | Pathological diagnosis of HCM 21 • The site and extent of left ventricular hypertrophy (LVH) in patients with hypertrophic cardiomyopathy (HCM) vary considerably. Right ventricular hypertrophy is also heterogeneous and might be concentric or localized to the apex, mid-septum, basal septum, or free wall. Prominent basal septal hypertrophy (sigmoid septum) is not diagnostic of HCM unless accompanied by myocyte disarray.
• Both interstitial and replacement fibrosis occur in HCM. Septal endocardial fibrosis just below the aortic valve (subaortic mitral impact lesion) is suggestive of HCM, but not pathognomonic, and also rarely occurs in systemic hypertension, aortic stenosis, and isolated basal septal hypertrophy. Diffuse endocardial thickening is nonspecific and observed in conjunction with a wide range of pathologies.
• Arteriolar density might be reduced in HCM. Small intramural vessels might show intimal and medial smooth muscle cell hyperplasia, with narrowing of the lumen, and are often surrounded by dense perivascular collagen.
• Myocyte disarray refers to haphazard alignment of adjacent myocytes (for example, perpendicular or oblique rather than parallel). Distribution is typically regional and might not coincide with the localization of hypertrophy. Detection is aided by extensive sampling of the full circumference at basal, mid-ventricular, and apical levels, using transverse rather than longitudinal sections. Although necessary for diagnosis of HCM, myocyte disarray is nonspecific, and occurs to a more limited extent in other settings including congenital cardiac anomalies. In the normal heart, small areas of disarray might be present in trabeculations and where the right ventricle interdigitates with the septum; the latter is often associated with interstitial adiposis. At present, no consensus regarding the minimum extent of myocyte disarray necessary for confirmation of HCM has been established, although a minimum of 10% has been recommended.
• Cardiomyocytes in HCM might have enlarged, pleomorphic, or hyperchromatic nuclei and disorganized myofibrillar architecture.
• Sarcoplasmic vacuolization in haematoxylin and eosin-stained sections should arouse suspicion of metabolic storage disease.
to provide additional prognostic information and to shed light on the aetiology of symptoms 13, 15, 51 . Echocardiography has an incontrovertible niche in the assessment of valve structure and function, and latent LVOTO. Despite the natural bias against replacing trusted modalities, slow implementation of new technologies, and delays in developing standardized protocols and measurements, cardiovascular magnetic resonance (CMR) is increasingly recognized as a valu able complement to echocardiography for the evaluation of HCM. In addition to not being limited by acoustic windows, CMR offers high spatial resolution and noninvasive, in vivo tissue characterization, with a number of accepted (BOX 2) and emerging indications 15, [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] 14, 15 , without adjustment for age, sex, or body surface area. Normal regional variations in LV wall thickness are not taken into account; consequently, the diagnostic threshold varies between 2 and 6 standard deviations above the normal adult mean depending on the segment under scrutiny 69 . The exclusive focus on maximal wall thickness (MWT) and reliance on cut-offs are a throwback to the era of M-mode echocardiography, when the full phenotypic spectrum awaited elucidation and the diagnostic capabil ities of imaging were limited. MWT is best viewed as an integral component of the diagnostic and prognostic profile of HCM, and requires careful measure ment at multiple levels. Outside of referral centres, it is not uncommon for the MWT measurement to have been made at the basal level only, or to have incorporated false tendons or right ventricular structures.
Both the ACCF/AHA and ESC guidelines recommend that diagnosis of HCM in children be based on LV wall thickness >2 standard deviations above the mean for age, sex, and body size -a necessary advance over unindexed cut-off values 14, 15 . The paediatric criteria have nonetheless been criticized for prioritizing increased sensitivity at the potential expense of specificity; the grey area separating physiological and pathological LVH is thought to fall between 2 and 3 standard deviations over the population mean 70 . As in adults, the presence of other abnormalities on ECG and echocardiography (such as diastolic dysfunction) facilitate differentiation of load-induced LVH from HCM in paediatric patients. A number of additional considerations influence management of HCM in children 3, 8, 35, [71] [72] [73] [74] [75] [76] [77] 
Diastolic functional assessment. In practice, much variation exists in the quality of diastolic functional assessment for HCM, although both sets of guidelines emphasize its importance, with the ESC specifying inclusion of Doppler myocardial imaging, pulmonary vein flow velocities, pulmonary artery systolic pressure, and measurement of left atrial (LA) size 15 . Not only is diastolic dysfunction one of the main causes of dyspnoea and exertional limitation in HCM, but it also serves as a risk predictor. In a study involving 239 consecutive patients with HCM, a restrictive LV filling pattern (ratio of mitral peak velocity of early filling [E] to mitral peak velocity of late filling [A] ≥2; E-wave deceleration time ≤130 ms) was an independent marker of increased risk of disease-related death or transplantation (HR 3.54, 95% CI 1.91-6.57, P <0.001) 78 .
Estimation of LA dimensions. Quantification of LA size is recommended as an indicator of filling pressures and clinical outcomes in HCM. The most reproducible linear measurement is the anteroposterior LA diameter, which has been extensively used in echocardiography practice and as a clinical marker. Given that
Box 3 | Emerging applications for CMR in HCM
• Gadolinium-based contrast (Gd-contrast) agents diffuse into the interstitial space without crossing intact cell membranes. A localized delay in the washout of Gd-contrast suggests coincident expansion of the available space, owing to myocyte loss, fibrosis, or an infiltrative process [62] [63] [64] . The paramagnetic properties of Gd-contrast result in shortening of T1 relaxation times in the region affected, generating a bright signal against the nulled normal myocardium in T1-weighted images [62] [63] [64] . Cardiac magnetic resonance (CMR) with late gadolinium enhancement (LGE) thereby facilitates diagnosis of phenotypic mimics of hypertrophic cardiomyopathy (HCM) 15, [59] [60] [61] [62] [63] [64] [65] [66] .
• Studies of the prognostic role of LGE in HCM have reported associations with progressive left ventricular (LV) remodelling (wall thinning, increasing end-systolic dimension), development of LV systolic dysfunction, deterioration to NYHA functional class III-IV, hospitalization for heart failure, heart failure-related death, ventricular tachycardia, cardiovascular mortality, and all-cause mortality 14, 15 . Evidence of influence on arrhythmic outcome is less robust; at present, LGE has not been definitively established as an independent predictor of sudden cardiac death. Possible reasons for the mixed results include differences in case mix and follow-up duration, in the rigour with which conventional risk profiling was performed, in the power achieved, and in the approach used to quantify LGE 15, 62 .
• LGE dichotomizes myocardium into bright (enhanced) versus dark (nulled), an oversimplification with twofold implications.
First, quantification of LGE is based on an operator-defined threshold of signal intensity, which might be anything from 2 to 6 standard deviations above normal myocardium, or assumption of full width at half maximal signal (FWHM), or entail manual delineation of 'regions of interest' 62 . Techniques that offer an approximation of the volume of a well-demarcated scar will prove more limited when applied to disease states such as HCM, in which fibrosis is less cohesive. Accordingly, the reproducibility of all quantification methods seems to be poorer in HCM than in acute or chronic myocardial infarction, although FWHM might be the most reliable 62 . Second, the absence of a reference region of normal myocardium renders LGE unsuitable for imaging diffuse fibrosis, which can generate an almost uniform myocardial signal intensity.
• Direct measurement of the longitudinal relaxation time (T1) in different areas of the myocardium, or T1 mapping, is an emerging solution to the challenge of visualizing diffuse processes [62] [63] [64] [65] .
• Cardiac T1 mapping before and after administration of Gd-contrast allows estimation of the myocardial volume of distribution of gadolinium, which reflects the extracellular volume fraction (ECV) [63] [64] [65] . The ECV is expanded in the presence of interstitial fibrosis. Available data indicate good correlation between ECV estimates from T1 mapping and the collagen volume fraction on histology [63] [64] [65] . Combined evaluation of focal and diffuse fibrosis using both LGE and T1 mapping techniques might enhance the utility of CMR as a prognostic tool in HCM.
LA remodel ling might not affect all wall dimensions to the same extent, however, there has been a push towards estimation of LA volumes, which are more accurate and show stronger clinical associations 79, 80 . The 2015 consensus guidelines for cardiac chamber quantification by echocardiography recommend 2D measurement of LA volume using the disk summation algorithm, followed by indexing to body surface area 81 . The reproducibility of indexed LA volume in a real-world setting is not well established and as a fairly recent adoption, data are not available for large-scale retrospective studies. As such, LA diameter remains the parameter of choice in many studies, including two multicentre investigations into factors influencing the risk of thromboembolism and SCD in HCM 82, 83 . As expected, LA diameter is increased in patients with HCM and atrial fibrillation (45.4 mm; 95% CI 41.6-49.0) versus sinus rhythm (38.0 mm; 95% CI 34.6-41.4) 84 . CMR-based evaluation of LA remodelling in HCM has further identified LA ejection fraction (<38%), LA end-diastolic volume (≥118 ml), and age (≥40 years) as independent predictors of atrial fibrillation 85 . LA diameter has also been shown to be an independent predictor of thrombo embolism (HR 1.03, 95% CI 1.01-1.05) in a multi variate analysis of 4,821 patients with HCM with or without atrial fibrillation over 10 years of follow-up. A positive linear relationship between LA diameter and the 5-year risk of thrombo embolism was observed up to 45-50 mm, at which point it became exponential. Among patients with HCM who were in sinus rhythm at baseline and had LA diameter >50 mm, the annual incidence of thrombo embolism (cerebro vascular accidents, transient ischaemic attack, or systemic peripheral embolus) was 0.47% 82 . While further investigation into the risk and benefits of anticoagulation in this subgroup is awaited, frequent and perhaps prolonged ambulatory ECG monitoring is warranted, as the burden of silent paroxysmal atrial fibrillation might be substantial. Other independent predictors of thromboembolism in the HCM cohort as a whole included age (HR 82 . By contrast, the CHA 2 DS 2 -VASc score seems to have low predictive accuracy for HCM, and its use is not recommended in this population; an alternative model for predicting the absolute 5-year risk of thromboembolism for patients with HCM has been proposed 82 . The predictive utility of LA remodelling extends beyond atrial fibrillation and thromboembolism. In HCM cohorts from both Italy and the USA, LA diameter >48 mm has been shown to be independently associated with a twofold increase in the risk of cardiovascular death after adjustment for age, sex, resting LVOTO, and atrial fibrillation 86 . The 2014 European model for SCD risk prediction in HCM includes LA diameter as one of its component markers 83 .
Limitations of LV ejection fraction.
Longitudinal contractile function in HCM is consistently reduced, both globally and regionally, coincident to the sites of hypertrophy. Evaluation of circumferential and radial function has produced discrepant results, with reports of both reduction and compensatory enhancement [87] [88] [89] . Nature Reviews | Cardiology Even when all components of strain (longitudinal, transverse, circumferential, and radial) are depressed, however, the LV ejection fraction often seems normal or increased, giving the false impression of 'good' systolic function 88 . The reason for this discrepancy has become apparent from mathematical modelling of LV contraction. LV ejection fraction has two determinants: myo cardial shortening (strain) and end-diastolic wall thickness; when the latter increases, so does radial wall thickening 90 . Consequently, the presence of LVH leads to overestimation of LV ejection fraction. A nomo gram with corrected LV ejection fractions for different LV wall thicknesses is now available, but awaits validation in the clinical setting 90 .
Pitfalls in the assessment of LVOTO. Besides being a major cause of symptoms in patients with HCM, LVOTO (≥30 mmHg) at rest is an independent predictor of HCM-related death (relative risk 1.6; P = 0.02) and, therefore, routinely sought during the initial diagnostic echocardiogram 91 . Image acquisition while the patient performs the Valsalva manoeuvre in sitting, semireclining, and -if necessary -standing positions is also recommended, although the prognostic effect of provocable obstruction remains unresolved 15 . In the absence of a haemodynamically significant (≥50 mmHg) resting or provocable LV outflow tract gradient, the AHA guidelines advise exercise stress echocardiography for identification of latent obstruction 14 . By contrast, the ESC approach is dependent on whether the individual has symptoms of LVOTO (such as dyspnoea, chest pain, exertional limitation, and/or impaired consciousness); if present, exercise stress echocardiography is warranted. For asymptomatic individuals, further investigation for latent LVOTO is not considered necessary unless "relevant to lifestyle advice and decisions on medical treatment" (REF. 15 ). In a study of 201 patients with HCM with gradients <50 mmHg at rest, 38% developed gradients ≥50 mmHg after exercise, lending support to the routine use of stress echocardiography 92 . Conversely, there is a paucity of evidence to suggest that latent LVOTO is an adverse prognostic indicator. As such, there might be little to be gained from instituting treatment in asymptomatic patients.
Obstacles to implementing the recommendations on exercise stress echocardiography include a lack of suitable facilities and staff with the required training and experience at most centres, including many tertiary referral units without a special interest in inherited cardiovascular disease. Consequently, pharmacological provocation with dobutamine and nitrates remains in widespread use, although they do not resemble physio logical stressors. Dobutamine is poorly tolerated, prone to yielding false positives, and best avoided, whereas nitrate use should be reserved for individuals unable to perform an exercise test 15 . Finally, Doppler Nature Reviews | Cardiology echocardiography for LVOTO, particularly during exercise studies, is often fraught with problems, most of which can be avoided by awareness and experience [93] [94] [95] [96] High-throughput genotyping. Both the ESC and ACCF/AHA guidelines recommend offering genetic testing to individuals with a confirmed clinical diagnosis of HCM, up to 60% of whom are expected to have an identifiable disease-causing variant. In the remaining cases, the result is either indeterminate (no suspicious variant found) or uncertain (because a variant of unknown significance has been found). Detection of the culprit mutation in a patient with HCM enables cascade screening of relatives, of whom ~50% on average will be noncarriers and can be afforded lifelong reassurance, while clinical surveillance is targeted to proven carriers 14, 15 . The pivotal challenge is determining whether an isolated sequence variant is pathogenic from multiple lines of evidence, including in silico models, in vitro functional and expression studies, co-segregation with clinical status in an affected family, alteration of an evolutionarily conserved amino acid residue, and absence or rarity among healthy control individuals.
The advent of massive parallel sequencing techniques, which are estimated to have reduced cost and enhanced throughput by more than threefold, has led to rising clinical demand for genetic testing. At the same time, growing public awareness of heritable disease through media coverage has increased uptake. At least part of the clinical need is met by commercial outsourcing, with many independent facilities also offering fee-based direct-to-consumer services. Screening is accomplished via large chips enriched for ≥50-200 cardiac genes or more open-ended whole-exome or whole-genome sequencing 97 . These high-output approaches are, however, proving a double-edged sword, by providing extensive coverage of implicated genes and plausible candidates on the one hand, while uncovering numerous sequence variants requiring bioinformatic and clinical interpretation on the other. The response to this challenge has been pragmatic, entailing a shift to probabilistic classification of variants ('pathogenic' , 'likely pathogenic' , 'uncertain significance' , 'likely benign' , and 'benign' , according to recommendations), coupled with a receptiveness to reclassification as more information emerges 20, 97 . The latter is of particular importance in relatives undergoing predictive testing, and is best broached during pretest counselling. Index cases who consent to whole-exome sequencing with a view to new gene discovery should be warned of the likelihood of incidental findings, such as detection of a familial cancer gene with uncertain clinical implications 97 . The bulk of the findings from high-throughput geno typing in patients with HCM have been consistent with those obtained from Sanger sequencing. Missense variants predominate (>75%), with small insertions and deletions accounting for most of the remainder 98 . Copy number variants, defined as genomic deletions and duplications >1 kb, seem to be present in <1% of patients with HCM, consistent with low tolerance of the sarcomeric genes to variation 99, 100 . The pick-up rate is otherwise similar; in a study of 223 unrelated patients with HCM, 131 (59%) had rare variants of likely or confirmed pathogenicity in sarcomeric, calcium-handling, and Z-disc genes (excluding titin), with most hits detected in MYBPC3 and MYH7, followed by TNNT2 and TNNI3 (REF. 101 ). An overlapping subgroup of 96 patients had nonsynonymous variants in desmosomal and ion-channel genes, but at frequencies not significantly different from those observed in the control popu lation. RYR2, CAV3, and SCN5A have previously been implicated in HCM, but the possibility now arises that their role is modifying rather than pathogenic 101 .
Box 4 | Special considerations in children with HCM
• The genetic profile of isolated hypertrophic cardiomyopathy (HCM) in children, whether sporadic or familial, includes a ~50% prevalence of sarcomeric mutations, most commonly in MYH7 and MYBPC3 (similar to that in adults) 73, 74 .
• Vigilance for phenocopies and genocopies of HCM takes on even greater importance in children 15 . . Among children with isolated HCM receiving implantable cardiac defibrillators for primary prevention, however, the annual incidence of appropriate intervention can be as high as 3.1% 75 .
The device-related complication rate is approximately 9.5% per year 75 , and psychosocial adjustment issues take on greater prominence in this age group, emphasizing the need for reliable risk stratification in paediatric HCM 3, 8, 15, 71, [75] [76] [77] .
• Development of a dedicated prognostic algorithm from existing data is impeded by heterogeneous inclusion criteria and frequent use of a combined end point, with few studies discriminating between arrhythmic and nonarrhythmic (heart failure-related) events. Proposed indicators of adverse outcome in isolated HCM include congestive heart failure, low weight, severe LVH, abnormal blood-pressure response to exercise, left atrial size, reduced left ventricular fractional shortening, decreased early transmitral flow velocity, nonsustained ventricular tachycardia, and QTc dispersion, with the latter two purportedly specific for arrhythmic outcome 3, 8, 71, [75] [76] [77] .
Perhaps the most striking example of genetic interaction in HCM is the gene-dose effect observed in patients with two (compound heterozygous, double heterozygous, or homozygous) or three sarcomeric mutations, who comprise ~5.0% and ~0.8% of reported series, respectively 102, 103 . Multiple 'hits' might pre dispose the affected individual to earlier onset of symptoms, greater septal wall thickness, increased risk of arrhythmic events, and progression to burnt-out disease [102] [103] [104] . Identification of a single pathogenic variant in a patient does not, therefore, obviate the need to screen the rest of the panel of HCM-related genes. Specific examples of nonsarcomeric modifiers in HCM include pro-LVH renin-angiotensin-aldosterone gene variants, which are associated with increased manifestation and severity of LVH and, in children, with progressive LVOTO 105, 106 . The prevalence of severe LVH (MWT ≥30 mm) seems to be significantly higher among patients with HCM harbouring rare variants in ANK2 (REF. 107 ). Variants in calciumhandling genes can also influence the expression and age of onset of LVH 98, 108 . Most of these purported modifying associations await further investigation in independent studies.
The ratio of published to novel variants in one of the high-throughput sequencing studies was 1:1, a departure from the abundant private mutations previously reported in HCM 101, 102 . An excess of private mutations in a genetically determined disease is usually contingent upon a high rate of spontaneous mutations, coupled with frequent prereproductive death, which prevents them from perpetuating in the gene pool. Neither condition is true of HCM, in which de novo mutations are recognized, but only ~15% of cases are sporadic and premature death is uncommon 102 . The prevalence of HCM-related variants in the general population might have been underestimated; sequencing of eight sarcomeric genes in 3,600 individuals from the Framingham and Jackson Heart study cohorts resulted in the identification of one or more probable pathogenic variants in 0.6% of patients (>1 in 200) 109, 110 . As genomic repositories grow, more private mutations might be reclassified as rare.
Although at least 1 in 200 of the general population might be carriers of pathogenic sarcomeric gene variants, estimates of the prevalence of HCM cluster around 1 in 500, suggesting either gene variants of markedly reduced penetrance and expressivity, or clinical underdiagnosis of the disease 109, 110 . In reality, a combination of the two factors is likely, given that a majority of the original prevalence studies enrolled unrelated adults only, employed a diagnostic criterion of MWT ≥15 mm, or both, thereby resulting in under-recognition of early, familial disease 110 .
Challenges in clinical diagnosis
Prospective evaluation of families. Among 90 carriers of HCM-related mutations, the proportion fulfilling conventional diagnostic criteria increased with age, from 55% in the 10-29 years age group, to 75% aged between 30 and 40 years, to 95% of those aged >50 years 111 . Given that the pretest probability is higher in relatives of patients with HCM, however, the diagnostic threshold is lowered to ≥13 mm in one or more LV myocardial segments 15 . Delayed onset (aged >40 years) is nevertheless recognized in troponin T and myosin essential light chain disease, and is particularly prominent among carriers of mutations in myosin binding protein C, a proportion of whom have MWT <13 mm when aged >60 years [112] [113] [114] . Age-related expression underpins consensus recommendations for lifelong surveillance of genetically affected individuals, which typically commences at ~10-12 years because clinical manifestations often develop during the pubertal growth spurt 14, 15 . Serial clinical . The anatomical level of the obstruction is pinpointed by sequential interrogation from LV apex to outflow with pulse-wave Doppler (PWD). Reliable assessment requires obtaining an acoustic window with a well-opened LVOT and high-quality spectral images, which can be complicated in the setting of distorted LV geometry, such as a bulging thickened anterobasal septum 14, 15, [93] [94] [95] . The challenge is compounded during exercise testing by upright posture and rapid, strenuous respiratory movements 14, 15, [93] [94] [95] .
• The main pitfall, however, is contamination of the LV outflow waveform by coexisting mitral regurgitation. The systolic anterior motion of the mitral valve that underlies LVOT obstruction is almost always accompanied by an inferolaterally directed jet of mitral regurgitation, which arises in mid-to-late systole in close anatomical proximity to the outflow stream. A mitral regurgitant jet that is centrally or anteriorly directed, on the other hand, warrants further investigation for intrinsic mitral valve abnormalities. An estimated LVOT velocity >5.0-5.5 m/s arouses suspicion of overlap with the mitral regurgitant trace and should prompt cautious reinterrogation of the Doppler signal. Despite an often trivial appearance on colour flow, the mitral regurgitation signal on CWD is usually strong, and discrimination between the two jets is dependent on recognizing their characteristic profiles 14, 15, [93] [94] [95] [96] (FIG. 5a-c ).
• Two other disease states occasionally confused with obstructive HCM are aortic stenosis and subaortic stenosis (either discrete or diffuse). Both types of stenoses are fixed obstructions present throughout systole, conferring on the CWD waveform a smoother contour and earlier peak. The third entity that warrants exclusion is the spurious obstruction caused by complete systolic emptying of a hyperdynamic left ventricle. Systolic anterior motion of the mitral valve, mitral-septal contact, an inflection point on the CWD trace, and the lobster claw abnormality on PWD are absent in all three states 14, 15, [93] [94] [95] [96] .
evaluation with 12-lead ECG and imaging is performed annually (twice yearly if borderline features are present) until physical maturity is attained, and every 5 years thereafter through adulthood. In the ~40% of families in whom no pathogenic mutation can be identified, the first-degree relatives of clinically affected patients should be offered surveillance on the basis that they are genotype-positive until proven otherwise.
Opinions differ as to whether children aged <10 years should undergo either clinical screening or predictive genetic testing, with the ESC guidelines advising to the contrary, unless they have a family history of earlyonset disease, show symptoms, or participate in highly strenuous physical activity 15 . The views of the parents should also be taken into account. Another grey area is whether clinical screening in families of unknown genetic status should extend to second-degree relatives, who for practical reasons are often overlooked, but might have inherited the trait from a parent with nonpenetrant disease.
A pressing need has arisen for characterization of early phenotypic features in HCM to monitor disease development in gene carriers and facilitate screening of families without an identifiable mutation. Previous efforts to do so focused on integrating mild morphological abnormalities identified on echocardiography with 12-lead ECG features, culminating in the 1997 criteria for familial HCM (TABLE 3) , long used in specialist centres to standardize diagnosis in relatives 115 . Since then, advances in imaging technology and biomarker analysis have further elucidated the spectrum of early disease [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] • Peak velocity in the LVOT (CWD trace)
• Coincides with nadir of velocity drop in the LV cavity (PWD trace)
• Instantaneous pressure gradient is at its maximum • LV cannot maintain ejection against sudden rise in afterload, resulting in transient cessation of LV longitudinal shortening and closure of aortic valve leaflets indicated in genotype-positive, LVH-negative individuals should be decided on a case-by-case basis, pending long-term observational studies to establish their clinical course and outcomes. Available data suggest that diastolic dysfunction and abnormal blood pressure response to exercise might precede the development of LVH, but their prognostic effect in this subgroup is unclear 40, 42, 115, 116 .
Isolated basal septal hypertrophy. IBSH, also known as sigmoid septum, becomes more common with advancing age, with a prevalence of 7.8% in patients aged >70 years 128 . Reports either suggest that the disease affects both sexes equally, or that there is increased prevalence in women, often on a background of hypertension 128, 129 . Clinical manifestations of IBSH include exertional limitation, chest pain, and dyspnoea that cannot be adequately explained by LV systolic dysfunction or coronary artery disease. Both diastolic dysfunction and systolic anterior motion of the mitral valve, resulting in dynamic LVOTO, have been implicated, with clinical improvement on β-blocker and disopyramide therapy; however, the prolonged mitral valve leaflets and papillary muscle abnormalities recognized in patients with HCM are usually absent 128, 129 . The presence of LVOTO in patients with IBSH seems to be related not to MWT, but to hypercontractile LV function and the position of the mitral valve leaflets with respect to the LV outflow tract 128 . Among 181 individuals with IBSH who underwent screening of eight HCM-related sarcomeric genes, causal mutations were isolated in only 15 (8%), considerably lower than the usual pick-up rate 130 . This finding suggests that a small proportion of individuals with IBSH have HCM, possibly late-onset or late-presenting, while a distinct pathophysiological mechanism is presumably at work in the remainder. The difficulty in establishing the aetiology of IBSH has little influence on management of the individual, but poses the dilemma of whether to offer screening to blood-relatives; genetic analysis might facilitate identification of the minority with underlying HCM, but a negative result does not exclude the disease. Clinical features that might enable distinction between HCM and nonheritable IBSH are yet to be identified. This knowledge gap has been acknowledged in the ESC guidelines, which recommend that the decision be partly based on the presence of symptoms in family members 15 .
Individuals of African descent.
In most racial groups, MWT ≥15 mm and repolarization abnormalities on 12-lead ECG distinguish HCM from load-induced LVH. By contrast, individuals of African-Caribbean descent seemed to have increased propensity towards LVH and repolarization changes at relatively low levels of cardiovascular stress (such as hypertension or athletic training) [131] [132] [133] . Ethnic variations in the normal ECG and echocardiogram compound the challenge of evaluating African-Caribbean individuals for inherited cardiovascular disease. In African-Caribbean patients with hypertension, the ESC guidelines recommend raising the diagnostic threshold for coexisting HCM to MWT ≥20 mm 15 . At the same time, HCM might be underrecognized among African-Caribbeans; in one US series, African-Americans accounted for 55% of competitive athletes who died suddenly with a postmortem diagnosis of HCM, but only 8% of clinically identified patients with HCM 131 . Cardiac evaluation of both athletes and healthy, nonathletic individuals of African ancestry has established many clinical features as benign. Examples include increased LV trabeculation, ST-segment elevation with upward domed convexity, and inverted T waves in V1-V4, which are prevalent among African-Caribbean individuals regardless of their sports participation history 15, 132, 133 . Findings are less clear-cut with respect to lateral T-wave inversion, which is considerably less prevalent (2.4-4.1% of African-Caribbean athletes and 0.7-3.4% of controls) and was present in two athletes who were subsequently diagnosed with HCM, one of whom suffered aborted cardiac arrest. Conversely, resolution of inferolateral T-wave inversion has also been observed in African-Caribbean athletes after a period of detraining 132, 133 . Large, long-term follow-up studies are awaited to define the implications of this diagnostic pattern among those of African ancestry.
Controversies in management
Risk stratification for SCD. Previous cardiac arrest or sustained ventricular tachycardia are unequivocal indications for ICD therapy for secondary prevention of SCD 14, 15 . All other individuals with a confirmed clinical diagnosis of HCM (both index cases and relatives) should be offered noninvasive prognostic assessment at baseline and follow-up (typically every 1-2 years) owing to the unpredictable and sometimes progressive disease course 14, 15 . The 2003 joint ACC/ESC consensus document on HCM amalgamated a number of outcome studies that identified prognostic indicators 13, 134 . The proposed risk stratification algorithm (FIG. 6) was widely and successfully adopted into clinical practice, albeit with considerable heterogeneity in the interpretation of the predictors; a family history of SCD, for example, was variously qualified to deaths in those aged >40 years or to deaths among first-degree relatives only 13, 134, 135 . As the limitations of the recommendations became apparent, however, various amendments were introduced, with the upshot that the 2011 ACCF/AHA and 2014 ESC guidelines now differ conspicuously in their approach to prognostication 14, 15 .
The threshold for intervention was revisited in a study of 506 patients with HCM who received ICDs, which found no difference in the likelihood of appropriate discharge between recipients with one, two, or three of the predictors evaluated. Several parameters were, however, omitted from the risk profile, including an abnormal blood-pressure response to exercise, ancillary markers such as ischaemia and LVOTO and, in 19% of the cohort, ambulatory ECG monitoring data 136 . Despite these drawbacks, the apparent presence of a single risk factor in more than one-third of ICD recipients with appropriate interventions provided much of the impetus for subsequent revision of the US recommendations. The 2011 ACCF/AHA guidelines upgraded three factors to class IIa (reasonable) indications for ICD therapy, while still recognizing the others as risk-predicting or risk-modifying 14 (FIG. 6) .
A validation study incorporating all five principal risk factors was subsequently conducted in 1,606 patients with HCM who were followed up for a median of 6.6 years 137 . Consistent with an additive effect, the cumulative incidence of SCD or appropriate ICD discharge was signifi cantly higher among patients with ≥2 versus zero risk factors (HR 3.3, 95% CI 1.94-5.75, P <0.001), although not in patients with one versus zero risk factors (HR 1.4, 95% CI 0.82-2.51, P = 0.212). Nevertheless, the original algorithm had several shortcomings. • Cardiac magnetic resonance (CMR) studies in carriers of HCM-related mutations have revealed a number of structural and functional abnormalities that precede the development of LVH, including: -Lower end-systolic volumes (38 ± 9 ml versus 43 ± 12 ml in controls) 117 . -Clefts are narrow recesses in the left ventricular (LV) wall, blood-filled and contiguous with the LV cavity, with a depth of ≥50% the thickness of the adjacent myocardium. Observed during diastole, clefts show at least partial systolic obliteration [118] [119] [120] [121] [122] . The presence of one or more clefts is twice as common among carriers of mutations in MYBPC3 than other genes (47% versus 23%; P = 0.045) 120 . Diagnostic utility depends on both location and number, with multiple clefts showing higher specificity, but lower sensitivity for mutation carriership [118] [119] [120] [121] [122] . Clefts seem to be less prevalent in overt HCM, regressing perhaps as the LV wall remodels, or becoming less easy to identify owing to diastolic compression by the thickened myocardium 122 .
-The anterior leaflet of the mitral valve is longer in mutation-carriers than matched controls (21 ± 3 mm versus 18 ± 3 mm) 123 .
-Apical LV trabeculation is more prominent among mutation-carriers than controls (1.25 ± 0.07 versus 1.20 ± 0.05), as quantified in terms of fractal dimension, a unitless measure of the geometric complexity of a structure 117 .
• A combination of the four CMR parameters described above can discriminate mutation carriers from healthy controls with an area under the receiver operating characteristic curve of 0.85 (REF. 120 ).
• Abnormal septal convexity has also been described on CMR examination of LVH-negative mutation carriers 124 .
• Rare cases have been reported of mutation carriers in whom symptomatic latent left ventricular outflow tract obstruction (LVOTO) -confirmed by exercise stress echocardiography -was the first clinical manifestation of the disease, preceding the development of LVH by ~2 years 127 . Pre-LVH abnormalities in mitral valve leaflet dimensions have been invoked as a possible predisposing factor 123 . Notably, however, exercise and dobutamine stress echocardiography can unmask latent LVOTO in many healthy individuals without LVH, which is nonspecific outside the context of familial HCM.
• Serum levels of the C-terminal propeptide of type I procollagen are also elevated in LVH-negative mutation carriers (107.73 ± 4.65 μg/l versus 82.16 ± 3.03 μg/l in controls; P <0.001), suggesting early activation of profibrotic pathways 125 . The late gadolinium enhancement technique allows visualization of focal fibrosis, but existing CMR studies indicate that this fibrosis does not appear until later in the disease course, after the onset of LVH. Emerging data suggest, however, that expansion of the extracellular matrix begins earlier and progresses with the disease 126 . CMR estimates of extracellular volume fraction were 0.27 ± 0.01 in controls versus 0.33 ± 0.01 in LVH-negative mutation carriers versus 0.36 ± 0.01 in LVH-positive patients with HCM 126 . First, of the 660 patients with no risk factors, 20 (3%) experienced a cardiac event (annual rate 0.45%, 95% CI 0.29-0.70), which precludes offering complete reassurance to any patient. Second, the positive predictive value for events was relatively low (22.4% for ≥2 risk factors), resulting in a sizeable proportion of patients being exposed to the risks of device implantation without tangible benefit. Third, the original algorithm assigned the 636 patients with one risk factor to an intermediate-risk stratum, with an annual event rate of 0.65%. Fourth, the area under the receiver operating characteristic curve (C-statistic) for prediction of arrhythmic events was 0.64 at 5 years, indicating limited power to discriminate high-risk from low-risk individuals 137 .
The novel SCD risk model now endorsed by the ESC was developed from a multicentre, retrospective, longitudinal cohort study of 3,675 patients with HCM with the aim of providing individualized 5-year risk estimates 83 . Putative risk factors were eligible only if identified from multivariate analysis, resulting in exclusion of abnormal blood-pressure response to exercise, upgrading of maximal LV outflow tract gradient at rest or during the Valsalva manoeuvre, and two new additions: age and LA diameter. The model predicts that for every 16 ICDs placed in patients with HCM at ≥4% 5-year risk of SCD, one individual will be saved from SCD at 5 years 83 . Independent validation studies have yielded mixed results, but most data suggest that the HCMRisk-SCD risk stratification algorithm outperforms both previous prognostication strategies. In a tertiary centre cohort of 706 patients with HCM who had not experienced previous events, the C-statistics for the 2003 algorithm, 2011 ACCF/AHA guidelines, and HCMRisk-SCD were 0.55, 0.60, and 0.69, respectively 138 . In a Spanish study of 48 patients with HCM who received an ICD, the HCM-Risk-SCD score was the only factor independently associ ated with the onset of ventricular tachyarrhythmia (OR 1.46, 95% CI 1.05-2.01), and none of the 11 patients with low-risk estimates experienced events 139 . A US report on 1,629 patients with HCM has proved the exception so far, with 21 out of 35 patients who experienced SCD or cardiac arrest apparently having low-risk scores (<4% at 5 years); however, few details of the prognostic assessment were provided 140 .
Criticisms of the HCM-Risk-SCD algorithm include limited applicability to children and those with phenotypic mimics of archetypal HCM, in whom validation data are currently lacking; failure to factor in the prognostic benefits of therapeutic measures such as invasive septal reduction, β-blockers, and amiodarone; and exclusion of ancillary predictors such as ischaemia 15, 83, 141 . The most important omission was an abnormal bloodpressure response to exercise, which has a 95% negative predictive value and is one of the most important factors for risk-stratifying individuals with minimal or severe LVH 40, 42, 142 . None of these drawbacks, however, will necessarily have an adverse effect on patient care, because the model does not seek to abrogate clinical experience or judgment. The achievement of the HCM-Risk-SCD score lies in the shift from relative to absolute risk estimation, which is more meaningful for the individual; future refinements will improve its generalizability and performance, pending additional data from intensive phenotyping and prospective validation studies.
Issues in the management of LVOTO. By international consensus, both septal myectomy and catheter-based transcoronary alcohol septal ablation (BOX 7) are best performed by experienced operators in the setting of a special ized programme 14, 15, [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] . High procedural volume might be associated with lower rates of in-hospital deaths and complications, from septal myectomy in particular 144, 145 . Patients with HCM are considered candi dates for invasive septal reduction in the presence of: resting or provoked LV outflow tract gradient ≥50 mmHg; sufficient anterior septal thickness (typically >16 mm); and either NYHA class III or IV limitation or exertional syncope or near-syncope, despite maximum-tolerated pharmacological therapy 14, 15, 134, 143 . Growing confidence in the net benefit of invasive septal reduction therapy at specialist HCM units has led to calls for more latitude in the eligibility criteria, so that the choice might be available to selected patients with NYHA class II symptoms after full discussion of the risks involved 161 . In children, septal myectomy is the recommended procedure because of its track record of efficacy, safety, and favourable long-term outcomes, although the small aortic annulus makes exposure more difficult and increases the risk of aortic (5.5%) or mitral (1.5%) valve injury 14, 15, 162, 163 . Recurrent obstruction is also more common in the paediatric population owing to ventricular remodelling 164 . In adults, the European guidelines for the management of HCM do not rank either option as superior to the other, but advocate preinterventional assessment of all patients by a multidisciplinary team to facilitate selection 15 . By contrast, the ACCF/AHA guidelines favour ventricular septal myectomy as first-line therapy, reserving alcohol septal ablation for patients who are either at high operative risk or wish to avoid surgery 14 . At least part of the justification for this preference might be reports that septal myectomy is an independent predictor of disease-related survival among patients with LVOTO, and of time to appropriate discharge among ICD recipients 141, 165 . Both gradient relief and substrate reduction have been invoked as possible explanations for the putative prognostic benefit of septal myectomy 141, 165, 166 . Furthermore, concerns persist regarding the arrhythmogenic potential of the scar generated by alcohol ablation, a major reason why the procedure is usually avoided in children. At least one study has identified an annual incidence of cardiac events fivefold higher after alcohol ablation than after myectomy (propensity score-adjusted HR 6.1, 95% CI 1.4-27.1) 134, 167 . To date, however, most meta-analyses have found alcohol septal ablation to be noninferior to myectomy in terms of subsequent functional improvement, short-term and longterm mortality, and -in one instance -superior with respect to SCD (OR 0.32, 95% CI 0.11-0.97) 151, [168] [169] [170] . In patients with HCM and drug-refractory LVOTO, but relatively mild LVH (≤16 mm), neither septal myectomy nor alcohol septal ablation is typically suitable owing to increased risk of iatrogenic ventricular septal defect. Dual-chamber pacing is one option, and pilot studies of biventricular pacing for LVOTO have also yielded promising results 14, 15, [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] 
. The alter native is to shift the target from the thickened septum to the abnormalities of the mitral valve and papillary muscles that predispose to systolic anterior motion, and for which both surgical and newer, catheter-based interventions are available 22, 171, 172 . One example of the latter is the MitraClip (Abbott Vascular), which has been successfully used to shift the residual anterior leaflet edge away from the LV outflow tract by combining it with the posterior leaflet (A2 to P2) in several cases 173 . Innovations in the surgical management of LVOTO include min imally invasive, robot-assisted myectomy, in which access to the septum is obtained via left atriotomy and through the mitral valve 174, 175 . Antibiotic prophylaxis for endocarditis. Damaged or abnormal native heart valves and any part of the endocardium disrupted by turbulent blood flow can become a nidus for bacterial seeding and consequent infective endocarditis. As a complication of HCM, infective endocarditis has been observed almost exclusively in patients with LVOTO (gradient ≥30 mmHg), in whom the annual incidence is estimated to be 0.38%, increasing to 0.92% in the presence of coexisting LA dilatation (≥50 mm) 176 . Precipitants such as recent dental work or other procedures were identified in four out of ten patients in one series; none had received coincident antibiotics 176 . Although no longer mandated by guidelines, the benefits of endo carditis prophylaxis might outweigh the minimal risks of antibiotic administration in this subgroup 177 .
Frontiers of therapy
The past decade has seen a number of therapies introduced and integrated into general cardiology practice and accepted in some settings as standard of care. Approval of these therapies for use in sub specialty practice is often won more slowly, because their safety and efficacy in subpopulations such as patients with inherited 
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Three or more consecutive beats at ≥120 bpm. ¶ Failure of systolic blood pressure (BP) to rise by ≥20 mmHg during maximal upright exercise testing; the prognostic value is greatest in those aged <40 years. cardiovascular disease have not been established. Examples include the direct-acting oral anticoagulants that selectively inhibit factor Xa (apixaban, edoxaban, and rivaroxaban) or thrombin (dabiga tran). The ESC guidelines advocate they be used in patients with HCM when vitamin K antagonists are unsuitable owing to failure to maintain thera peutic anticoagulation, adverse effects, or inability to undertake international normalized ratio (INR) monitor ing 15 . Dabigatran receives mention in the ACCF/AHA guidelines as a non inferior alternative to vitamin K antagonists for thromboprophylaxis in atrial fibrillation, with the caveat that data in patients with HCM are not available 14 .
Catheter ablation for atrial fibrillation has not only grown almost exponentially in popularity, but is also increasingly considered a first-line treatment for selected patients in general cardiology practice. Metaanalyses suggest a complication rate in patients with HCM similar to that in the general population, offset by a greater need for repeat procedures and antiarrhythmic drugs to prevent atrial fibrillation recurrence 178, 179 . Putative predictors of relapse after ablation include LA remodelling and diastolic dysfunction, with conflicting data on LVOTO 178, 179 . Criteria for selecting the patients with HCM most likely to benefit from atrial fibrillation ablation remain to be established.
Subcutaneous ICDs hold particular appeal for individ uals with HCM, many of whom will have devices in situ for decades, and exposed to the risk of leadrelated complications. Although most patients with HCM have no pacing requirement, estimates vary as to the proportion who satisfy the additional prerequisite of suitable vectors on surface ECG screening. Eligibility rates of 84-93% have been reported, being higher when right parasternal leads are tested and lower among high-risk patients 180, 181 . High T-wave voltages seem to be the main cause of screening failure, consistent with an increased prevalence of inappropriate shocks owing to T-wave oversensing among patients with HCM and subcutaneous devices [181] [182] [183] . Proposed solutions to this issue include careful monitoring of device recipients, exercise testing during screening and follow-up, and fine-tuning of the discrimination algorithm, perhaps by adding a 2.5 mm/mV gain setting [180] [181] [182] .
Towards substrate-modulating therapy. As reninangiotensin system inhibitors and other vasodilators can worsen haemodynamics in patients with HCM and resting or latent LVOTO, their use is currently limited to the burnt-out phase of HCM, which is characterized by systolic dysfunction and managed with conventional heart failure therapy 14, 15, 92 . Whether renin-angiotensin
Box 7 | Invasive septal reduction therapies
• Septal myectomy entails thoracotomy, cardiopulmonary bypass, and resection of the hypertrophied basal septum via transaortic approach or, less commonly, through the left atrium and mitral valve 143, 149, 150 . Aside from complications pertaining to general anaesthesia and open heart surgery, a <2% risk of aortic dissection and/or aortic or mitral valve injury exists [143] [144] [145] [146] [147] [148] [149] [150] [151] . Surgical candidates can expect a ~5-day initial hospital stay and substantial postoperative recovery time 143 . Gradient alleviation, however, is immediate. Resection can be customized to the complex anatomy of the outflow tract and extended distally in the presence of midcavity obstruction. Often performed in conjunction with mitral valve interventions such as repair, plication, replacement, or papillary muscle realignment, myectomy can also be combined with other surgical procedures, such as coronary artery bypass grafting or aortic valve replacement [143] [144] [145] [146] [147] [148] [149] [150] [151] .
• Alcohol septal ablation is a percutaneous procedure offering shorter hospital stay and more rapid recovery than with septal myectomy. The general complication profile is similar to angioplasty, with the added risk (7-20%) of permanent pacemaker implantation, which is approximately twofold higher than that associated with myectomy 15, 143, 144, 147 . Feasibility depends on the availability of a septal perforator that supplies a territory confined to the obstructive part of the hypertrophic septum. Contrast echocardiography facilitates delineation of the area of perfusion; if the area does not include the target septal segments, or extends to remote regions of the myocardium, another septal perforator is cannulated or the procedure is abandoned 15, 147 . Selection of a suitable branch of the left anterior descending artery is followed by alcohol injection to induce localized myocardial necrosis 15, 147 . Many patients demonstrate a triphasic haemodynamic response, with immediate marked relief of left ventricular outflow tract (LVOT) obstruction (LVOTO) secondary to stunning or myocardial oedema. As the myocardium recovers from the initial insult, however, the gradient might return to 50% of its preprocedure level; sustained reduction ensues gradually over weeks to months as scarring, thinning, and remodelling occur 15, 147 .
• Dual chamber (DDD) pacing is purported to alleviate LVOTO by two main mechanisms. During systole, right ventricular apex pacing results in paradoxical movement of the interventricular septum, which increases the dimensions of the LVOT. During diastole, the atrioventricular interval is programmed such that the timing of atrial systole allows maximal left ventricular filling 15, 152 . Small (n <100) observational studies and randomized trials suggest that DDD pacing results in a modest gradient reduction, with subjective symptomatic benefit; objective improvement in functional capacity has been reported in patients aged >65 years 15, [152] [153] [154] [155] [156] [157] . As such, DDD pacing is offered as second-line therapy when other interventions are deemed too high risk or have been declined 14, 15 . For patients with HCM requiring dual-chamber pacemakers for other indications, however, it makes sense to optimize settings for relief of LVOTO 14, 15 . The use of biventricular pacing to reduce LVOTO in patients with HCM with indications for ICD therapy or contraindications to septal myectomy and alcohol septal ablation remains under investigation. Pilot series involving 11-12 patients reported improvements in NYHA class and objective measures of exercise capacity, with progressive reduction in both the LVOT gradient and the grade of mitral regurgitation over 1-3 years, accompanied by regression of LVH 152, [158] [159] [160] . The benefits have been tentatively ascribed to altered contraction of a large area of the left ventricle, with earlier longitudinal displacement of the lateral wall and diminished peak longitudinal displacement of the septum Figure 7 | Calcium handling and the actin myosin crossbridge cycle in cardiac muscle. a | Calcium handling in the cardiomyocyte. b | The myosin head binds strongly to ATP. ATP is hydrolysed to ADP and inorganic phosphate (P i ), which remain bound to myosin; the energy released locks the myosin head into a pre-stroke configuration. Voltage-gated L-type Ca 2+ channels open during phases 0 and 1 of the cardiac myocyte action potential, allowing a small influx of Ca 2+ ions. This influx in turn activates cardiac ryanodine receptors (RyR), triggering much greater release of stored, calsequestrin-bound Ca 2+ ions from the sarcoplasmic reticulum (calcium-induced calcium release, CICR). The rapidly rising cytosolic calcium activates troponin C (TnC), which pulls tropomyosin out of its groove on the actin filament. Binding sites for myosin are now lying exposed on the actin filament. Myosin-ADP-P i binds to actin, weakly at first. P i is subsequently released, resulting in stronger binding of myosin-ADP to actin. This weak-to-strong transition is generally the rate-limiting step in the actin-myosin crossbridge cycle. The myosin power stroke happens next (force-producing state). Subsequent release of ADP frees the myosin head to dissociate from actin and bind preferentially to ATP again. Relaxation of the cardiac myocyte during diastole is dependent on calcium being extruded from the cell by the Na + /Ca 2+ exchanger and the sarcolemmal Ca 2+ pump, and sequestered back into the sarcoplasmic reticulum by the sarco/ endoplasmic reticulum Ca 2+ -ATPase (SERCA2a) pump, which is inhibited by dephosphorylated phospholamban (PLB). TnI, troponin I; TnT, troponin T.
system inhibitors might exert a disease-modifying effect on LVH and fibrosis earlier in the course of nonobstructive HCM has been the subject of several trials. A pilot study in which 20 patients with nonobstructive HCM were randomly assigned to receive placebo or losartan for 1 year reported a significantly larger increase in the extent of late gadolinium enhancement in the control group 184 . The subsequent randomized, controlled INHERIT trial 185 (n = 133), however, showed no significant differences in left ventricular mass, global longitudinal strain, Doppler measures of diastolic function, or LA volume between the losartan and placebo groups after 12 months. Recruitment is ongoing for the VANISH trial 186 , which is designed to evaluate the safety and efficacy of valsartan in preventing disease progression among mutation carriers, either LVH-negative or LVH-positive (with NYHA class I-II symptoms).
Approaches for substrate modification are currently in development, and range from metabolic modulators to small-molecule effectors and gene therapies for 'rescuing' HCM at the level of the biomechanical defect. The myocyte action potential, calcium handling, sarcomeric function, and energy utilization serve as the primary targets 18, 52, [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] . Laboratory studies of cardiomyocytes from patients with HCM undergoing septal myectomy have demonstrated electrophysiological abnormalities including prolonged action potential duration and increases in the late Na + and Ca 2+ currents, diastolic Ca 2+ concentration, and the occurrence of early and delayed after depolarizations 187, 188 . The late sodium current inhibitor ranolazine -better known as an antianginal drug -partially reversed these effects in vitro, reducing arrhythmogenicity and improving diastolic function in ventricular trabeculae 187, 188 . Results are awaited from RESTYLE-HCM 189 , a double-blind, placebocontrolled study of the effect of ranolazine on exercise capacity in patients with symptomatic HCM; a similar trial, , to assess the new selective late sodium current inhibitor eleclazine is ongoing.
One popular school of thought holds that HCMrelated mutations sensitize the myofilaments to calcium -shifting the force-calcium concentration curve to the left (FIG. 8) -and augment the overall power output of the cardiac muscle, resulting in hypercontractility and impaired relaxation 191, 192 . The clinical applicability of these findings has been evaluated in a pilot, double-blind trial of diltiazem versus placebo in LVHnegative carriers of sarcomeric mutations over a 3-year treatment period 194 . Carriers of mutations in MYBPC3 (n = 12), but not MYH7 (n = 21), showed significant improvements over controls in echocardio graphic MWT, CMR-measured LV mass index, and diastolic filling (E/Eʹ) 194 . The variable efficacy of drugs affecting myocardial Ca 2+ handling might be related to the proportion of HCM mutations that demonstrate the reverse pattern: Ca 2+ desensitization, with a rightward shift of the forcepCa curve (FIG. 8) , or attenuation of the overall power output 195 . The genetic locus also does not offer any guide to functional effect; different mutations in MYH7, for example, exert opposing effects on myofilament Ca 2+ sensitivity and contractility 195 . For any given mutation, however, the properties of the affected myocardium can be elucidated anew and treatment tailored accordingly. Pending the advent of reliable in silico models, these data can be sought through in vitro studies.
Motility assays are typically performed using purified recombinant sarcomeric protein constructs containing the mutation under investigation 196 . A single-molecule dual-beam optical trap allows direct measurement of Small-molecule modulators can then be designed to counteract the effects of the mutation. Strategies to modify ensemble force generation include altering the affinity of the interaction of myosin-binding protein C with its binding sites on myosin. If more myosin heads are functionally inhibited by myosin-binding protein C, there will be fewer available to interact with actin (N t ), and vice versa. Alternatively, force generation can be modified by changing the pace of the weak to strong transition, which will affect the total cycle time (t c ), and hence the duty ratio t s /t c (the ratio of the time spent in a strongly-bound state to the total cycle duration) 191, 199 .
For example, the myosin-ATPase inhibitor MYK-461 reduces the rate of phosphate release without slowing ADP release, thereby increasing t c without increasing t s , leading to a decrease in the duty ratio t s /t c , and reduction in both ensemble force and power 200 . In mice with hypercontractile mutations in myosin heavy chain, early chronic administration of MYK-461 prevented the development of LVH, myocyte disarray, and fibrosis, and normalized expression of profibrotic and mitochondrial genes involved in energy utilization 200 . Preliminary data from phase I clinical trials indicate that MYK-461 is well tolerated with dose-dependent pharmacokinetics 201 . Force-pCa relationships have also been investigated at the molecular level using the three-bead optical trap assay and a mini-ensemble of myosin heads, but additional insights into the pathogenesis of HCM have been gained from studies of single muscle fibres 195 . The latter are most readily sourced from slow-twitch skeletal muscle fibres, which express sarcomeric mutations and have the advantages of being easily biopsied and less prone to the adaptive responses observed in myocardium 195 . Sensitizing and desensitizing HCM mutations shift the average force-pCa relationship to the left and right, respectively (FIG. 8d) . One aberration shared by the mutated muscle samples, however, is a wider spread among the constituent curves, indicating greater divergence in the behaviour of individual fibres than wild-type. This observation might be attributable to the range of mutant mRNA found in individual muscle fibres (10-100%) and in individual cardiomyocytes 195, 197 . The observed functional variation between mutated cardiomyocytes and muscle fibres, if true for HCM in general, might be the final common pathway of disease expression 197 . Uneven force generation in branching cellular networks lead to imbalances in contraction, stretch, and relaxation, which result in transient and ultimately chronic structural distortion 197 . Inefficient ATP usage is another likely consequence, tying in with the energy depletion hypothesis (FIG. 10) 52 . Increased expression of trophic factors ensues, with development of hypertrophy and interstitial fibrosis; accumulating evidence points to oxidative stress as an exacerbating factor 52, 197 . This paradigm has at least twofold consequences for therapy. First, generic treatments that exert the same effect on all cardiomyocytes are likely to have limited efficacy. Second, the need to target specific mutations (with, for example, small-molecule effectors) or a unifying mechanism (such as energy depletion or oxidative load) is underscored 197 . One of the first efforts to correct the myocardial energy deficit was a randomized, controlled trial to compare the metabolic modulator perhexiline with placebo in 46 participants with HCM over 3-6 months 202 . The treatment group showed significant improvements in peak oxygen consumption during exercise, NYHA class, diastolic function, and myocardial ratio of phosphocreatine to ATP (a marker of cardiac energetic status), as measured by 31 P magnetic resonance spectroscopy 202 . Perhexiline is a carnitine palmitoyl-acyltransferase inhibitor that shifts mitochondrial metabolism from fatty acid to carbohydrate utilization, leading to Figure 9 | Assessing force production, velocity, and power output of the cardiac sarcomere. a | The equation on the left enables calculation of the ensemble force (F e ) of the sarcomere as the product of the intrinsic force of each myosin head (f), the total number of myosin heads functionally able to interact with actin filaments (N), and the ratio of the time spent in a strongly-bound state to the total cycle duration (t s /t c ), which determines the proportion of myosin heads in a force-producing state. The lower equation estimates the unloaded velocity (v) from the myosin head stroke size (d) divided by the strongly-bound state time (t s ). The power output of the sarcomere is represented by the area under the load-velocity curve. As the ensemble force and/or velocity increase, so does the power output, as shown in the graph. b | A dual-beam, three-bead optical trap. Both ends of a single actin filament are attached to 1 µm polystyrene beads, which are held in place by two focused infrared (IR) laser beams. Beneath this 'actin dumbbell' is a single myosin molecule attached to a 1.5 µm polystyrene platform bead fixed on a coverslip surface. The position-sensitive detectors can accurately gauge even 1 nm of movement in the beads. This assay allows direct measurement of the intrinsic force (f), strongly bound state time (t s ), and stroke size 
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Position sensitive detector oxygen-sparing effects and enhanced myocardial efficiency. Adverse effects associated with long-term use of perhexiline include hepatitis and peripheral neuropathy, but as with amiodarone, the risk can be minimized by maintaining plasma concentrations within the thera peutic margin 203 . In 2015, a phase III trial of per hexiline in 350 participants with moderate-to-severe HCM was announced 204 .
Administration of the antioxidant glutathione precursor N-acetylcysteine (NAC) to animal models of HCM is reported to have normalized the ratio of oxidized glutathione to total glutathione and the levels of glutathiolated myofilaments, with reversal of increased myofilament Ca 2+ sensitivity, hypertrophy, interstitial fibrosis, and diastolic dysfunction 205, 206 . The ongoing phase I HALT study 207 aims to determine the adverse effect and compliance profile of an oral formulation of NAC, and its effect on LV mass and other structural and functional indices in patients with overt HCM 18 .
Conclusions
Guideline-driven medical practice has many benefits, including its capacity to extend standards of care for uncommon or challenging diseases to general cardiologists. Expert consensus reached during development of guidelines, however, cannot expect to capture the limitations in present understanding of complex clinical entities. Conflicting advice on the evaluation and manage ment of HCM, for example, is largely a reflection of differences in the parsing of incomplete, albeit hard-won, data on the disease. In this Review, we have sought to uncover some of the strengths and shortcomings of the current knowledge base. The goal is transparency over dictum; although we have far greater knowledge than we did 50 years ago, the majority of existing studies are observational, frequently singlecentre, and limited by historical context, while their findings are generally concordant but far from monolithic. We encourage practitioners to bring the power of expert consensus avail able in authored guidelines to the clinical setting, while maintaining a discerning position towards the robustness of each recommendation. The role of subspecialist opinions and referral units also remains firmly intact, as there is no substitute for cumulative clinical and technical experience, dedicated facilities, and multidisciplinary support staff in the prov ision of nuanced care for patients in this perpetually evolving field. 
